Commenting on new Alzheimer's drug, solanezumab, Professor John Hardy
(UCL Molecular
Neuroscience) said that if the drug worked as suggested then it could be
hugely important as a signpost for future research.
Read: Times (£),
More: Guardian,
Daily Mail,
The Australian,
The Observer
Close
